Last reviewed · How we verify
NCT03556046
89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE
Phase 1 trial testing 89Zr-Girentuximab in Clear Cell Renal Carcinoma in 10 participants. Completed in 17 December 2018.
17 December 2018
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 10 |
| Start date | 5 April 2018 |
| Primary completion | 17 December 2018 |
| Estimated completion | 17 December 2018 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- 89Zr-Girentuximab — full drug profile →
Conditions studied
- Clear Cell Renal Carcinoma — all drugs for Clear Cell Renal Carcinoma →
Sponsor
Radboud University Medical Center
Who can join
50 and older, any sex, with Clear Cell Renal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is designed to explore the safety and tolerability as well as diagnostic 89Zr-girentuximab for imaging CCRC by PET/CT. This study does not offer any treatment for patients with CCRC; therefore, patients will be offered state of the art therapeutic options after imaging with the study drug 89Zr-girentuximab. Cancer treatment will not be delayed by study participation.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment strategies for clear cell renal cell carcinoma: Past, present and future.
Yang J, Wang K, Yang Z. · · 2023 · cited 49× · PMID 37025584 · DOI 10.3389/fonc.2023.1133832 -
Phase I study to assess safety, biodistribution and radiation dosimetry for <sup>89</sup>Zr-girentuximab in patients with renal cell carcinoma.
Merkx RIJ, Lobeek D, Konijnenberg M, Jiménez-Franco LD, et al · · 2021 · cited 44× · PMID 33651116 · DOI 10.1007/s00259-021-05271-w -
Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.
Dubois J, Deshayes E, Kucharczak F, Cadet MM, et al · · 2026 · PMID 42012571 · DOI 10.1186/s41181-025-00418-8
Verify or expand the search:
- PubMed search for NCT03556046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 89Zr-Girentuximab
Trials testing the same drug.
- NCT07077083 — CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC · Phase 2 · not yet recruiting
- NCT05861778 — Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear · Phase 1 · completed
- NCT05046665 — Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients · Phase 1 · completed
Other recruiting trials for Clear Cell Renal Carcinoma
Currently open trials in the same condition.
- NCT06940518 — Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma · Phase 2 · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03556046 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 1 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03556046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing